

AmpliPhi Biosciences Announces Presentation of Bacteriophage Therapy Case Studies at American Society of Microbiology Annual Meeting

“These case studies indicate that AB-SA01 may be safely administered intravenously in the critically ill and may have a role to play in the management of severe staphylococcal sepsis, for patients with resistant and life-threatening infections”

SAN DIEGO--([BUSINESS WIRE](#))--AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced a late-breaker poster presentation describing four case studies of patients suffering from severe *Staphylococcus aureus* (*S. aureus*) infections, who received treatment with AB-SA01, AmpliPhi's investigational bacteriophage drug candidate. The presentation will be made at the American Society for Microbiology (ASM) Microbe 2018 annual meeting, being held June 7-11, 2018 in Atlanta. The abstract can be viewed [here](#).

Poster Presentation:

Title: AAR LB16 - Bacteriophages as adjuvant therapy for the treatment of severe staphylococcal sepsis

Date and time: Friday, June 8, 2018, 11 a.m. - 1 p.m. EDT

Session: 048 - FRIDAY - AAR Late-breakers

Track: AAR

Location: Exhibit and Poster Hall, Building B, Halls B2-B5, Georgia World Congress Center, Atlanta, Georgia

Presenter: Dr. Jonathan Iredell, Westmead Hospital and Westmead Institute for Medical Research

The presentation describes the use of an intravenously administered investigational bacteriophage therapeutic AB-SA01, being developed by AmpliPhi, to treat critically ill patients suffering from severe *S. aureus* infections. The patients treated included three cases of endovascular infection and one case of severe vertebral osteomyelitis with epidural abscess. In all cases, available medical and surgical therapy was deemed to be inadequate before starting bacteriophage therapy.

AB-SA01 was well-tolerated, with no treatment related adverse outcomes reported, and bacterial elimination was demonstrated in three out of four patients.

“These case studies indicate that AB-SA01 may be safely administered intravenously in the critically ill and may have a role to play in the management of severe staphylococcal sepsis, for patients with resistant and life-threatening infections,” said Dr. Jonathan Iredell, Infectious Diseases Physician and Clinical Microbiologist at the Westmead Hospital, Professor of Medicine and Microbiology at the University of Sydney, and the treating physician for these cases.

About AmpliPhi Biosciences

AmpliPhi Biosciences Corporation is a clinical-stage biotechnology company focused on treating antibiotic-resistant infections using its proprietary bacteriophage-based technology. AmpliPhi's lead product candidates, AB-SA01 and AB-PA01, target multidrug-resistant *Staphylococcus aureus* and *Pseudomonas aeruginosa*, which are included on the WHO's 2017 Priority Pathogens List. Phage therapeutics are uniquely positioned to address the threat of antibiotic-resistance as they can be precisely targeted to kill select bacteria, have a differentiated mechanism of action, can penetrate and disrupt biofilms (a common bacterial defense mechanism against antibiotics), are potentially synergistic with antibiotics and have been shown to restore antibiotic sensitivity to drug-resistant bacteria. For more information visit www.ampliphio.com.

Forward Looking Statements

Statements in this press release that are not statements of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, without limitation, statements regarding: the potential benefits of phage therapy; the potential use of bacteriophages to treat bacterial infections, including infections that do not respond to antibiotics or are associated with biofilms. Words such as “believe,” “anticipate,” “plan,” “expect,” “intend,” “will,” “may,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. Among the factors that could cause actual results to differ materially from those indicated in these forward-looking statements are risks and uncertainties associated with bacteriophage product candidate development, both generally and specifically

through expanded access regulations, AmpliPhi's financial condition, and other risks and uncertainties described in AmpliPhi's Annual Report on Form 10-K for the year ended December 31, 2017, as filed with the Securities and Exchange Commission (SEC), and AmpliPhi's subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and AmpliPhi undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

CONTACT:

At the Company:
AmpliPhi Biosciences
Matthew Dansey
(858) 800-4869

md@ampliphio.com

or

Investor Relations:
Westwicke Partners
Robert H. Uhl
(858) 356-5932

robert.uhl@westwicke.com

<https://investor.armatapharma.com/2018-06-07-AmpliPhi-Biosciences-Announces-Presentation-of-Bacteriophage-Therapy-Case-Studies-at-American-Society-of-Microbiology-Annual-Meeting>